Unilife — Q2 2012 Earnings Presentation
21 slides from Unilife's earnings presentation, Feb 10, 2012
Slide 1: Second Quarter 2012 Earnings Conference Call
Second Quarter 2012 Earnings Conference Call February 9, 2012
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains forward looking statements under the safe harbor provisions of the US securities laws. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our mana
Slide 3: Corporate Overview
Corporate Overview Alan Shortall Chief Executive Officer
Slide 4: Capital raise strengthens cash position; on track for Unifill supply contracts
Corporate Update Corporate Update Capital raise strengthens cash position and institutional holdings On track for Unifill supply contracts Device development across all platforms Continuing R&D investment to address other unmet needs
Slide 5: An Innovative, Highly Differentiated Portfolio
An Innovative, Highly Differentiated Portfolio Enabling and enhancing the delivery of injectable therapies
Slide 6: Unilife Delivery Systems
Unilife Delivery Systems Unifill Unitract Auto-Infusor Unifill Select Rita Auto Injector EZMix
Slide 7: Prefilled Syringes with Integrated Safety: The Unifill Syringe
Prefilled Syringes with Integrated Safety The Unifill Syringe 100% user acceptance in human factor studies Commercial supply contracts on track Expected finalization of current negotiations in CY 2012 A primary drug container, a safety device and a needle containment system
Slide 8: Prefilled Syringes with Integrated Safety: The Unifill Select
Development completed, now in pilot production phase Expected agreements in CY 2012 Prefilled Syringes with Integrated Safety The Unifill Select All the features of the Unifill syringe, with the addition of attachable needles
Slide 9: Drug Reconstitution Delivery Systems: EZMix
Drug Reconstitution Delivery Systems EZMix Only dual-chamber prefilled syringe with integrated safety Generating strong commercial interest Commercialization expected in 2013 One step for reconstitution of dry drugs with the safe, intuitive injection
Slide 10: Novel Devices for Targeted Organ Delivery
Novel Devices for Targeted Organ Delivery Confidential program with global pharmaceutical company Clinical Development Agreement signed in November 2011 $1.4 million in initial revenues To be recognized during next two quarters (up to end June 2012) Successful development of devices Supply for use i
Slide 11: Auto-Injectors: Unilife Rita Auto-Injector
Auto-Injectors Unilife Rita Auto-Injector Designed for use with Unifill syringe Pilot production underway A highly compact auto-injector, and the only one with true end-of dose indicators
Slide 12: Auto-Infusion Systems: Auto-Infusors
Auto-Infusion Systems Auto-Infusors The only delivery system ready for use with human clinical drug trials for large volume doses 5mL and over 3mL to 15mL variants developed Initial supply of evaluation units to pharmaceutical customers completed this current quarter Supply for use with clinical dru
Slide 13: Capital Raise
Capital Raise Raised capital to fund development and commercial supply of advanced drug delivery systems, and expand workforce Net proceeds of $33.8 million (excluding greenshoe option) Oversubscribed, low discount to market Consisted of U.S. institutional healthcare investors Sole book running mana
Slide 14: Financial Data Overview
Financial Data Overview Rich Wieland Chief Financial Officer
Slide 15: Financial Data - Fiscal 2nd Quarter 2012
Revenues for the quarter of $0.9M, compared to $1.8M for 2Q 2011 According to our business strategy, product sales reflect the discontinuing of contract manufacturing operations in December 2010 Industrialization and development fees increased $0.2M related to the clinical development and supply of
Slide 16: Financial Data - Fiscal 2nd Quarter 2012 Continued
Net loss for the quarter was $12.9M, or $0.19 per diluted share, compared to a net loss of $10.4M, or $0.19 per diluted share for 2Q 2011 R&D expenses increased by $2.8M due to additional payroll costs and expenditures related to the development of additional advanced drug delivery devices Partially
Slide 17: Financial Data - Adjusted Net Loss and Balance Sheet Data
Adjusted net loss of $9.6M, or $0.14 per diluted share, compared to an adjusted net loss of $7.6M, or $0.14 per diluted share for 2Q 2011 Excludes approx. $3.3M in non-cash share-based compensation expense, depreciation and amortization and interest expense compared to $2.7M in non-cash items in 2Q
Slide 18: Looking Ahead in FY2012
Looking Ahead in FY2012 Alan Shortall Chief Executive Officer
Slide 19: Stock Purchase Activities by CEO
Stock Purchase Activities by CEO Purchased more than $1 million in shares of UNIS common stock over last month in the open market. Mr. Shortall is the largest shareholder in Unilife. Follows prior market purchases of more than $1.5 million of UNIS common stock during calendar year 2011.
Slide 20: Looking Forward for Calendar Year 2012
Continued Unifill supplies to current and new customers Unifill placement onto stability studies Potential for additional access or royalty fees Commercial supply agreements Agreements for additional products within portfolio Develop or customize Unilife devices to address specific customer needs fo
Slide 21: Questions
Questions